blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3394105

EP3394105 - CHIMERIC ANTIGEN RECEPTOR WITH CYTOKINE RECEPTOR ACTIVATING OR BLOCKING DOMAIN [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  19.05.2023
Database last updated on 14.06.2024
FormerThe patent has been granted
Status updated on  10.06.2022
FormerGrant of patent is intended
Status updated on  21.02.2022
FormerExamination is in progress
Status updated on  19.07.2019
FormerRequest for examination was made
Status updated on  28.09.2018
FormerThe international publication has been made
Status updated on  05.07.2017
Formerunknown
Status updated on  24.01.2017
Most recent event   Tooltip14.06.2024Lapse of the patent in a contracting state
New state(s): MC, TR		published on 17.07.2024 [2024/29]
Applicant(s)For all designated states
Miltenyi Biotec B.V. & Co. KG
Friedrich-Ebert-Strasse 68
51429 Bergisch Gladbach / DE
[2019/46]
Former [2018/44]For all designated states
Miltenyi Biotec GmbH
Friedrich-Ebert-Strasse 68
51429 Bergisch Gladbach / DE
Inventor(s)01 / ABKEN, Hinrich
Gotthard-Bauer-Str. 1
94333 Geiselhöring-Hainsbach / DE
02 / HOMBACH, Andreas
Parkstraße 10
50321 Brühl / DE
 [2018/46]
Former [2018/44]01 / ABKEN, Hinrich
Rhönstr. 1a
56414 Meudt / DE
02 / HOMBACH, Andreas
Parkstraße 10
50321 Brühl / DE
Representative(s)Biervert, Christian
c/o Miltenyi Biotec B.V. & Co. KG
Corporate Legal Department
Friedrich-Ebert-Straße 68
51429 Bergisch Gladbach / DE
[2022/28]
Former [2018/44]Biervert, Christian
Miltenyi Biotec GmbH
Corporate Legal Department
Friedrich-Ebert-Straße 68
51429 Bergisch Gladbach / DE
Application number, filing date16826024.820.12.2016
[2018/44]
WO2016EP81944
Priority number, dateEP2015020262523.12.2015         Original published format: EP 15202625
[2018/44]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017108805
Date:29.06.2017
Language:EN
[2017/26]
Type: A1 Application with search report 
No.:EP3394105
Date:31.10.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 29.06.2017 takes the place of the publication of the European patent application.
[2018/44]
Type: B1 Patent specification 
No.:EP3394105
Date:13.07.2022
Language:EN
[2022/28]
Search report(s)International search report - published on:EP29.06.2017
ClassificationIPC:C07K16/30, C07K14/54, C07K14/725, C07K14/705
[2018/44]
CPC:
C07K16/3007 (EP,US); A61K39/00117 (US); A61K39/4611 (EP);
A61K39/4631 (EP); A61K39/46444 (EP); A61K39/46447 (EP);
A61K39/464482 (EP); A61P35/00 (EP); C07K14/5434 (EP,US);
C07K14/7051 (EP,US); C07K14/70521 (EP,US); C12N5/0636 (EP);
A61K2039/505 (EP,US); A61K2239/31 (EP); A61K2239/38 (EP);
A61K2239/59 (EP); C07K2317/622 (EP,US); C07K2317/64 (EP,US);
C07K2319/03 (EP); C07K2319/31 (EP); C07K2319/33 (EP);
C07K2319/75 (EP); C12N2510/00 (EP) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/44]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:CHIMÄRER ANTIGENREZEPTOR MIT ZYTOKINREZEPTORAKTIVIERENDER ODER -BLOCKIERENDER DOMÄNE[2018/44]
English:CHIMERIC ANTIGEN RECEPTOR WITH CYTOKINE RECEPTOR ACTIVATING OR BLOCKING DOMAIN[2018/44]
French:RÉCEPTEUR D'ANTIGÈNE CHIMÉRIQUE AVEC ACTIVATION DE RÉCEPTEUR DE CYTOKINE OU DOMAINE DE BLOCAGE[2022/11]
Former [2018/44]RÉCEPTEUR D'ANTIGÈNE CHIMÉRIQUE AVEC DOMAINE D'ACTIVATION OU DE BLOCAGE DE RÉCEPTEUR DE CYTOKINE
Entry into regional phase17.07.2018National basic fee paid 
17.07.2018Designation fee(s) paid 
17.07.2018Examination fee paid 
Examination procedure17.07.2018Examination requested  [2018/44]
17.07.2018Date on which the examining division has become responsible
04.01.2019Amendment by applicant (claims and/or description)
23.07.2019Despatch of a communication from the examining division (Time limit: M04)
12.11.2019Reply to a communication from the examining division
02.04.2020Despatch of a communication from the examining division (Time limit: M04)
29.07.2020Reply to a communication from the examining division
26.11.2020Despatch of a communication from the examining division (Time limit: M04)
15.03.2021Reply to a communication from the examining division
22.02.2022Communication of intention to grant the patent
07.06.2022Fee for grant paid
07.06.2022Fee for publishing/printing paid
07.06.2022Receipt of the translation of the claim(s)
Opposition(s)14.04.2023No opposition filed within time limit [2023/25]
Fees paidRenewal fee
17.07.2018Renewal fee patent year 03
13.12.2019Renewal fee patent year 04
14.12.2020Renewal fee patent year 05
24.12.2021Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU20.12.2016
AL13.07.2022
AT13.07.2022
CY13.07.2022
CZ13.07.2022
DK13.07.2022
EE13.07.2022
FI13.07.2022
HR13.07.2022
LT13.07.2022
LV13.07.2022
MC13.07.2022
MK13.07.2022
PL13.07.2022
RO13.07.2022
RS13.07.2022
SE13.07.2022
SI13.07.2022
SK13.07.2022
SM13.07.2022
TR13.07.2022
NO13.10.2022
GR14.10.2022
IS13.11.2022
PT14.11.2022
IE20.12.2022
LU20.12.2022
[2024/29]
Former [2024/27]HU20.12.2016
AL13.07.2022
AT13.07.2022
CY13.07.2022
CZ13.07.2022
DK13.07.2022
EE13.07.2022
FI13.07.2022
HR13.07.2022
LT13.07.2022
LV13.07.2022
MK13.07.2022
PL13.07.2022
RO13.07.2022
RS13.07.2022
SE13.07.2022
SI13.07.2022
SK13.07.2022
SM13.07.2022
NO13.10.2022
GR14.10.2022
IS13.11.2022
PT14.11.2022
IE20.12.2022
LU20.12.2022
Former [2024/21]HU20.12.2016
AL13.07.2022
AT13.07.2022
CY13.07.2022
CZ13.07.2022
DK13.07.2022
EE13.07.2022
FI13.07.2022
HR13.07.2022
LT13.07.2022
LV13.07.2022
PL13.07.2022
RO13.07.2022
RS13.07.2022
SE13.07.2022
SI13.07.2022
SK13.07.2022
SM13.07.2022
NO13.10.2022
GR14.10.2022
IS13.11.2022
PT14.11.2022
IE20.12.2022
LU20.12.2022
Former [2024/18]HU20.12.2016
AL13.07.2022
AT13.07.2022
CZ13.07.2022
DK13.07.2022
EE13.07.2022
FI13.07.2022
HR13.07.2022
LT13.07.2022
LV13.07.2022
PL13.07.2022
RO13.07.2022
RS13.07.2022
SE13.07.2022
SI13.07.2022
SK13.07.2022
SM13.07.2022
NO13.10.2022
GR14.10.2022
IS13.11.2022
PT14.11.2022
IE20.12.2022
LU20.12.2022
Former [2023/48]AL13.07.2022
AT13.07.2022
CZ13.07.2022
DK13.07.2022
EE13.07.2022
FI13.07.2022
HR13.07.2022
LT13.07.2022
LV13.07.2022
PL13.07.2022
RO13.07.2022
RS13.07.2022
SE13.07.2022
SI13.07.2022
SK13.07.2022
SM13.07.2022
NO13.10.2022
GR14.10.2022
IS13.11.2022
PT14.11.2022
IE20.12.2022
LU20.12.2022
Former [2023/38]AL13.07.2022
AT13.07.2022
CZ13.07.2022
DK13.07.2022
EE13.07.2022
FI13.07.2022
HR13.07.2022
LT13.07.2022
LV13.07.2022
PL13.07.2022
RO13.07.2022
RS13.07.2022
SE13.07.2022
SI13.07.2022
SK13.07.2022
SM13.07.2022
NO13.10.2022
GR14.10.2022
IS13.11.2022
PT14.11.2022
LU20.12.2022
Former [2023/37]AL13.07.2022
AT13.07.2022
CZ13.07.2022
DK13.07.2022
EE13.07.2022
FI13.07.2022
HR13.07.2022
LT13.07.2022
LV13.07.2022
PL13.07.2022
RO13.07.2022
RS13.07.2022
SE13.07.2022
SI13.07.2022
SK13.07.2022
SM13.07.2022
NO13.10.2022
GR14.10.2022
IS13.11.2022
PT14.11.2022
Former [2023/29]AL13.07.2022
AT13.07.2022
CZ13.07.2022
DK13.07.2022
EE13.07.2022
FI13.07.2022
HR13.07.2022
LT13.07.2022
LV13.07.2022
PL13.07.2022
RO13.07.2022
RS13.07.2022
SE13.07.2022
SK13.07.2022
SM13.07.2022
NO13.10.2022
GR14.10.2022
IS13.11.2022
PT14.11.2022
Former [2023/23]AT13.07.2022
CZ13.07.2022
DK13.07.2022
EE13.07.2022
FI13.07.2022
HR13.07.2022
LT13.07.2022
LV13.07.2022
PL13.07.2022
RO13.07.2022
RS13.07.2022
SE13.07.2022
SK13.07.2022
SM13.07.2022
NO13.10.2022
GR14.10.2022
IS13.11.2022
PT14.11.2022
Former [2023/22]AT13.07.2022
CZ13.07.2022
DK13.07.2022
FI13.07.2022
HR13.07.2022
LT13.07.2022
LV13.07.2022
PL13.07.2022
RO13.07.2022
RS13.07.2022
SE13.07.2022
SM13.07.2022
NO13.10.2022
GR14.10.2022
IS13.11.2022
PT14.11.2022
Former [2023/21]DK13.07.2022
FI13.07.2022
HR13.07.2022
LT13.07.2022
LV13.07.2022
PL13.07.2022
RS13.07.2022
SE13.07.2022
SM13.07.2022
NO13.10.2022
GR14.10.2022
IS13.11.2022
PT14.11.2022
Former [2023/20]FI13.07.2022
HR13.07.2022
LT13.07.2022
LV13.07.2022
PL13.07.2022
RS13.07.2022
SE13.07.2022
SM13.07.2022
NO13.10.2022
GR14.10.2022
IS13.11.2022
PT14.11.2022
Former [2023/12]FI13.07.2022
HR13.07.2022
LT13.07.2022
LV13.07.2022
PL13.07.2022
RS13.07.2022
SE13.07.2022
NO13.10.2022
GR14.10.2022
IS13.11.2022
PT14.11.2022
Former [2023/11]FI13.07.2022
HR13.07.2022
LT13.07.2022
LV13.07.2022
PL13.07.2022
RS13.07.2022
SE13.07.2022
NO13.10.2022
GR14.10.2022
PT14.11.2022
Former [2023/10]FI13.07.2022
HR13.07.2022
LT13.07.2022
LV13.07.2022
RS13.07.2022
SE13.07.2022
NO13.10.2022
GR14.10.2022
PT14.11.2022
Former [2023/09]FI13.07.2022
LT13.07.2022
LV13.07.2022
RS13.07.2022
SE13.07.2022
NO13.10.2022
PT14.11.2022
Former [2023/08]FI13.07.2022
LT13.07.2022
RS13.07.2022
SE13.07.2022
NO13.10.2022
Cited inInternational search[XI]  - M. CHMIELEWSKI ET AL, "IL-12 Release by Engineered T Cells Expressing Chimeric Antigen Receptors Can Effectively Muster an Antigen-Independent Macrophage Response on Tumor Cells That Have Shut Down Tumor Antigen Expression", CANCER RESEARCH, (20110708), vol. 71, no. 17, doi:10.1158/0008-5472.CAN-11-0103, ISSN 0008-5472, pages 5697 - 5706, XP055185302 [X] 1-6,8,10-13 * page 5699, column l, paragraph 5 - column r; figures 1, 2C, 2E * [I] 9

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-11-0103
 [XY]  - MARKUS CHMIELEWSKI ET AL, "TRUCKs: the fourth generation of CARs", EXPERT OPINION ON BIOLOGICAL THERAPY, ASHLEY, LONDON; GB, (20150518), vol. 15, no. 8, doi:10.1517/14712598.2015.1046430, ISSN 1471-2598, pages 1145 - 1154, XP055271031 [X] 1-5,8,10-13 * page 1147, column l - page 1150, column l; figures 1,2; table 1 * [Y] 6,9

DOI:   http://dx.doi.org/10.1517/14712598.2015.1046430
 [Y]  - SADELAIN M ET AL, "The promise and potential pitfalls of chimeric antigen receptors", CURRENT OPINION IN IMMUNOLOGY, ELSEVIER, OXFORD, GB, vol. 21, no. 2, doi:10.1016/J.COI.2009.02.009, ISSN 0952-7915, (20090401), pages 215 - 223, (20090325), XP026058399 [Y] 6,9 * table 1 *

DOI:   http://dx.doi.org/10.1016/j.coi.2009.02.009
 [X]  - MARKUS CHMIELEWSKI ET AL, "Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma", IMMUNOLOGICAL REVIEWS, (20140113), vol. 257, no. 1, doi:10.1111/imr.12125, ISSN 0105-2896, pages 83 - 90, XP055185690 [X] 1-6,8,10-13 * the whole document *

DOI:   http://dx.doi.org/10.1111/imr.12125
 [A]  - BLAT DAN ET AL, "Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells.", MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY MAY 2014, (201405), vol. 22, no. 5, ISSN 1525-0024, pages 1018 - 1028, XP002758115 [A] 1-6,8-13 * abstract *

DOI:   http://dx.doi.org/10.1038/mt.2014.41
 [A]  - BURGA RACHEL A ET AL, "Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T.", CANCER IMMUNOLOGY, IMMUNOTHERAPY : CII JUL 2015, (201507), vol. 64, no. 7, ISSN 1432-0851, pages 817 - 829, XP002758116 [A] 1-6,8-13 * abstract *

DOI:   http://dx.doi.org/10.1007/s00262-015-1692-6
 [A]  - JOSE A FIGUEROA ET AL, "Chimeric Antigen Receptor Engineering: A Right Step in the Evolution of Adoptive Cellular Immunotherapy", INTERNATIONAL REVIEWS OF IMMUNOLOGY, HARWOOD ACADEMIC PUBLISHERS, LONDON, GB, (20150101), vol. 34, ISSN 0883-0185, pages 154 - 187, XP009189941 [A] 1-6,8-13 * page 159, paragraph 2 - page 160, paragraph 1; figure 2 *
ExaminationWO2017032777
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.